Clinical Trial Update: IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma [Phase 1]

View source ↗

Summary

Phase 1 trial update for IM83 CAR-T cell therapy in relapsed or refractory osteosarcoma; the study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• IM83 CAR-T cell therapy (IM83 CAR-T)

Snippet

Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd. | Conditions: Refractory Osteosarcoma, Recurrent Osteosarcoma | Phase 1 | Status: NOT_YET_RECRUITING